Zoladex® is a Luteinising Hormone-Releasing Hormone analogue (LHRHa). Zoladex® is available as a 3.6 mg implant and a LA 10.8 mg implant in a pre-filled syringe.
Indications and Usage
Zoladex 3.6mg Implant and Zoladex LA 10.8mg Implant are both indicated for:
(i) Treatment of prostate cancer in the following settings:
- In the treatment of metastatic prostate cancer where Zoladex has demonstrated comparable survival benefits to surgical castrations
- In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Zoladex has demonstrated comparable survival benefits to an anti-androgen
- As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival and overall survival
- As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival
- As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Zoladex has demonstrated improved disease-free survival. For further details, please refer to Section 5.1 of the SPC
Zoladex 3.6mg Implant is further indicated for:
(ii) Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation.
(iii) Zoladex 3.6 mg is indicated as an alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogenreceptor (ER) positive early breast cancer.
(iv) Endometriosis: In the management of endometriosis, Zoladex alleviates symptoms, including pain, and reduces the size and number of endometrial lesions.
(v) Endometrial thinning: Zoladex is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection.
(vi) Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery.
(vii) Assisted reproduction: Pituitary downregulation in preparation for superovulation.